Targeting the ERG oncogene with splice-switching oligonucleotides as a novel therapeutic strategy in prostate cancer

BACKGROUND: The ERG oncogene, a member of the ETS family of transcription factor encoding genes, is a genetic driver of prostate cancer. It is activated through a fusion with the androgen-responsive TMPRSS2 promoter in 50% of cases. There is therefore significant interest in developing novel therape...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Ling, Hobson, Lisa, Perry, Laura, Clark, Bethany, Heavey, Susan, Haider, Aiman, Sridhar, Ashwin, Shaw, Greg, Kelly, John, Freeman, Alex, Wilson, Ian, Whitaker, Hayley, Nurmemmedov, Elmar, Oltean, Sebastian, Porazinski, Sean, Ladomery, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7493922/
https://www.ncbi.nlm.nih.gov/pubmed/32581342
http://dx.doi.org/10.1038/s41416-020-0951-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7493922/
https://www.ncbi.nlm.nih.gov/pubmed/32581342
http://dx.doi.org/10.1038/s41416-020-0951-2

Ejemplares similares